Biomarkers Products & Reviews

COVID-19, MERS & SARS-CoV, Nucleoprotein Antibody, 1058

SARS-CoV-2 Nucleocapsid, clone 504 Monoclonal Antibody (matched pair with clone 502 or 503)

SARS-CoV-2 Nucleocapsid, clone 2A1 Monoclonal Antibody (matched pair with clone 2C1)

SARS-CoV-2 Nucleocapsid, clone 2C1 Monoclonal Antibody (matched pair with clone 2A1)

SARS-CoV-2 Nucleocapsid, clone 4D8 Monoclonal Antibody (matched pair with clone 5B7)

SARS-CoV-2 Nucleocapsid, clone 5B7 Monoclonal Antibody (matched pair with clone 4D8)

SARS-CoV-2 Nucleocapsid,clone 7B3 Monoclonal Antibody (matched pair with clone 5D4)

SARS-CoV-2 Nucleoprotein (aa 1-419) Recombinant Antigen, 613

SARS-CoV-2 Spike (RBD, aa 331-524) Recombinant Antigen

SARS-CoV-2 Spike Protein S1 (aa 1-674) Recombinant Antigen

IRDye® Click Chemistry reagents (DBCO, Alkyne, and Azide) offer convenient, versatile and reliable methods for biomolecule labeling. With a variety of in vitro and in vivo applications, from biomarker isolation to assay development.

Sino Biological provides a wide range of influenza virus research reagents and technical services, supporting vaccine safety and immunogenicity assessment and vaccine protective efficacy evaluation.

Sino Biological offers a wide range of products and services to provide customers with complete multispecific antibody development solutions covering various phases of the development process, such as antibody development and optimization, druggability assessment, animal model evaluation, and process development.

Sino Biological provides comprehensive solutions for CAR-T cell therapy companies from CAR development, T cell activation, lentivirus packaging, CAR-T cell expansion to CAR-T cell quality control, fully supporting CAR-T research.

Sino Biological has developed a series of high-quality research reagents for dominant SARS-CoV-2 mutants, including recombinant antigens, detection antibodies, ELISA kits, pseudovirus, cDNAs, peptide pools, and receptor ACE2. These variant reagents have actively supported the basic research of SARS-CoV-2 and the development of vaccines, therapeutic antibodies, and diagnostic reagents.

Sino Biological provides comprehensive reagents and services for CAR-NK cell therapy development to support our customers from early target discovery to the preclinical phase of research and development.

Cytokines and their receptors show great potential in tumor immunotherapy, and many cytokines have been identified as targets for tumor drug development. Sino Biological's cytokines support stem cells, neural cells, immune cells, and organoids, facilitating functional studies and accelerating scientific discoveries.

Sino Biological has developed an extensive suite of recombinant complement proteins, covering C1s, C2, C3, C5, C7, Factor B, D, H, I and more, advancing the development of novel treatments targeting complement proteins.

Sino Biological offers a comprehensive range of recombinant HER3 proteins and antibodies, facilitating studies on HER3 signaling, protein-protein interactions, and drug efficacy assessments.

Sino Biological provides a comprehensive range of recombinant CEACAM proteins and corresponding CEACAM antibodies for crucial research, aiding investigations into CEACAM interactions with pathogens and their potential in new medical discoveries.

Unleash the full power of a well-designed library. With Twist Bioscience, you are assured that the library you design contains the specific modifications, exactly where you want them, saving you valuable resources for the downstream screening process.

Twist Biopharma, a division of Twist Bioscience, provides services to help accelerate the way our partners discover and optimize antibody therapeutics with our unique DNA writing technology. Twist constructs proprietary antibody libraries precisely designed to match sequences that occur in the human body giving our partners an integral and unbiased resource for antibody therapeutic discovery and optimization.

Twist Biopharma, a division of Twist Bioscience, provides services to help accelerate the way our partners discover and optimize antibody therapeutics with our unique DNA writing technology. Twist constructs proprietary antibody libraries precisely designed to match sequences that occur in the human body giving our partners an integral and unbiased resource for antibody therapeutic discovery and optimization.

sTNFRr1 is a predictive marker of Chronic Kidney Disease (CKD) and End Stage Renal Disease (ESRD)

Greiner Bio-One  offers a comprehensive range of state-of-the-art solutions for large biorepository cryo storage